IL4R and Alzheimer disease: Dupilumab, a monoclonal anti-IL-4Rα antibody, induces tissue reversal of the AD phenotype in the skin, improving both skin barrier function and immune dysregulation, and the molecular changes are parallel with clinical improvement [51, 52].